i
Implementation of RotaVirus Surveillance and Vaccine Introduction — World Health Organization African Region, 2007–2016
-
Nov 03 2017
-
-
Source: MMWR Morb Mortal Wkly Rep. 66(43):1192-1196.
[PDF-504.16 KB]
Details:
-
Alternative Title:MMWR Morb Mortal Wkly Rep
-
Personal Author:
-
Corporate Authors:
-
Description:RotaVirus is a leading cause of severe pediatric diarrhea globally, estimated to have caused 120,000 deaths among children aged <5 years in sub-Saharan Africa in 2013 (1). In 2009, the World Health Organization (WHO) recommended rotaVirus vaccination for all infants Worldwide (2). Two rotaVirus vaccines are currently licensed globally: the monovalent Rotarix vaccine (RV1, GlaxoSmithKline; 2-dose series) and the pentavalent RotaTeq vaccine (RV5, Merck; 3-dose series). This report describes progress of rotaVirus vaccine introduction (3), coverage (using estimates from WHO and the United Nations Children's Fund [UNICEF]) (4), and impact on pediatric diarrhea hospitalizations in the WHO African Region. By December 2016, 31 (66%) of 47 countries in the WHO African Region had introduced rotaVirus vaccine, including 26 that introduced RV1 and five that introduced RV5. Among these countries, rotaVirus vaccination coverage (completed series) was 77%, according to WHO/UNICEF population-weighted estimates. In 12 countries with Surveillance data available before and after vaccine introduction, the proportion of pediatric diarrhea hospitalizations that were rotaVirus-positive declined 33%, from 39% preintroduction to 26% following rotaVirus vaccine introduction. These results support introduction of rotaVirus vaccine in the remaining countries in the region and continuation of rotaVirus Surveillance to monitor impact.
-
Subjects:
-
Source:
-
Pubmed ID:29095805
-
Pubmed Central ID:PMC5689217
-
Document Type:
-
Place as Subject:
-
Volume:66
-
Issue:43
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
